{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:38:21Z","timestamp":1792625901862,"version":"4.5.0"},"reference-count":178,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1053\/j.ajkd.2026.07.006","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:22:37Z","timestamp":1792570957000},"page":"645-681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["KDOQI Commentary on the 2025 AHA\/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults"],"prefix":"10.1053","volume":"88","author":[{"given":"Tara I.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Cluett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Drawz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna Q.","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboob","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Awdishu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1053\/j.ajkd.2026.07.006_bib1","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1053\/j.ajkd.2026.07.006_bib2","first-page":"e426","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"issue":"9","key":"10.1053\/j.ajkd.2026.07.006_bib3","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamacardio.2020.1731","article-title":"Association of normal systolic blood pressure level with cardiovascular disease in the absence of risk factors","volume":"5","author":"Whelton","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"12","key":"10.1053\/j.ajkd.2026.07.006_bib4","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"38","key":"10.1053\/j.ajkd.2026.07.006_bib5","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1053\/j.ajkd.2026.07.006_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002389","article-title":"Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis","volume":"14","author":"Tucker","year":"2017","journal-title":"PLoS Med"},{"issue":"10","key":"10.1053\/j.ajkd.2026.07.006_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jamainternmed.2023.3264","article-title":"Effects of cuff size on the accuracy of blood pressure readings: the Cuff(SZ) randomized crossover trial","volume":"183","author":"Ishigami","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1053\/j.ajkd.2026.07.006_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/ANNALS-24-00873","article-title":"Effects of noise and public setting on blood pressure readings: a randomized crossover trial","volume":"178","author":"Ishigami","year":"2025","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1053\/j.ajkd.2026.07.006_bib9","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/archinte.1991.00400070157022","article-title":"Aneroid sphygmomanometers: an assessment of accuracy at a university hospital and clinics","volume":"151","author":"Bailey","year":"1991","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1053\/j.ajkd.2026.07.006_bib10","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.881701","article-title":"Limitations of the of the oscillometric method for blood pressure measurements in dialyzed patients","volume":"17","author":"Czarkowski","year":"2011","journal-title":"Med Sci Monit"},{"issue":"22","key":"10.1053\/j.ajkd.2026.07.006_bib11","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2026.07.006_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.125.24527","article-title":"Evidence-based, streamlined approach to measure blood pressure in primary care settings","volume":"83","author":"Foti","year":"2026","journal-title":"Hypertension"},{"issue":"4S","key":"10.1053\/j.ajkd.2026.07.006_bib13","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2026.07.006_bib14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"issue":"4","key":"10.1053\/j.ajkd.2026.07.006_bib15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.mayocp.2020.07.037","article-title":"Adherence to chronic kidney disease screening guidelines among patients with type 2 diabetes in a US administrative claims database","volume":"96","author":"Folkerts","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1053\/j.ajkd.2026.07.006_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.26230","article-title":"Estimated prevalence and testing for albuminuria in US adults at risk for chronic kidney disease","volume":"6","author":"Chu","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1053\/j.ajkd.2026.07.006_bib17","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2337\/dc21-0723","article-title":"Chronic kidney disease testing among at-risk adults in the U.S. remains low: real-world evidence from a national laboratory database","volume":"44","author":"Alfego","year":"2021","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1053\/j.ajkd.2026.07.006_bib18","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.34067\/KID.0000000922","article-title":"Implementation of a kidney screening intervention to improve early CKD detection in adults with diabetes","volume":"6","author":"Spolnik","year":"2025","journal-title":"Kidney360"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.7326\/M14-1539","article-title":"Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force","volume":"162","author":"Piper","year":"2015","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2026.07.006_bib21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2215\/CJN.08530815","article-title":"Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage","volume":"11","author":"Drawz","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib22","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2215\/CJN.05391008","article-title":"Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis","volume":"4","author":"Bangash","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2026.07.006_bib23","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2215\/CJN.13181117","article-title":"Variations in 24-hour BP profiles in cohorts of patients with kidney disease around the world: the I-DARE Study","volume":"13","author":"Drawz","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2026.07.006_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/jch.13760","article-title":"Patient perceptions of ambulatory blood pressure monitoring testing, tolerability, accessibility, and expense","volume":"22","author":"Ringrose","year":"2020","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"8","key":"10.1053\/j.ajkd.2026.07.006_bib25","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s11606-023-08036-3","article-title":"Acceptability and adherence to home, kiosk, and clinic blood pressure measurement compared to 24-h ambulatory monitoring","volume":"38","author":"Thompson","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"1","key":"10.1053\/j.ajkd.2026.07.006_bib26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/HYPERTENSIONAHA.124.23678","article-title":"Home blood pressure measurements are not performed according to guidelines and standardized education is urgently needed","volume":"82","author":"Clapham","year":"2025","journal-title":"Hypertension"},{"issue":"11","key":"10.1053\/j.ajkd.2026.07.006_bib27","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2020030236","article-title":"Prognostic significance of ambulatory BP monitoring in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"31","author":"Rahman","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2026.07.006_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1055\/a-1134-4980","article-title":"Hypokalemia and the prevalence of primary aldosteronism","volume":"52","author":"Gruber","year":"2020","journal-title":"Horm Metab Res"},{"issue":"11","key":"10.1053\/j.ajkd.2026.07.006_bib44","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1053\/j.ajkd.2026.07.006_bib45","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S2468-2667(17)30003-8","article-title":"The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis","volume":"2","author":"Roerecke","year":"2017","journal-title":"Lancet Public Health"},{"issue":"2","key":"10.1053\/j.ajkd.2026.07.006_bib46","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026477","article-title":"Coffee and green tea consumption and cardiovascular disease mortality among people with and without hypertension","volume":"12","author":"Teramoto","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10.1053\/j.ajkd.2026.07.006_bib47","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/jhh.2017.45","article-title":"The association between consistent licorice ingestion, hypertension and hypokalaemia: a systematic review and meta-analysis","volume":"31","author":"Penninkilampi","year":"2017","journal-title":"J Hum Hypertens"},{"issue":"6","key":"10.1053\/j.ajkd.2026.07.006_bib48","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/CIRCULATIONAHA.121.056015","article-title":"Regular acetaminophen use and blood pressure in people with hypertension: the PATH-BP trial","volume":"145","author":"MacIntyre","year":"2022","journal-title":"Circulation"},{"issue":"9","key":"10.1053\/j.ajkd.2026.07.006_bib49","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1751-7176.2011.00509.x","article-title":"Central sympatholytic drugs","volume":"13","author":"Vongpatanasin","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"4","key":"10.1053\/j.ajkd.2026.07.006_bib50","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/HYPERTENSIONAHA.119.13341","article-title":"Paroxysmal hypertension associated with presyncope","volume":"74","author":"Luther","year":"2019","journal-title":"Hypertension"},{"issue":"4","key":"10.1053\/j.ajkd.2026.07.006_bib51","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1682","article-title":"ADHD diagnosis and treatment guidelines: a historical perspective","volume":"144","author":"Wolraich","year":"2019","journal-title":"Pediatrics"},{"issue":"4","key":"10.1053\/j.ajkd.2026.07.006_bib52","article-title":"Acute blood pressure changes associated with antipsychotic administration to psychiatric inpatients","volume":"20","author":"Parks","year":"2018","journal-title":"Prim Care Companion CNS Disord"},{"issue":"10","key":"10.1053\/j.ajkd.2026.07.006_bib53","doi-asserted-by":"crossref","first-page":"736","DOI":"10.5498\/wjp.v11.i10.736","article-title":"Antipsychotics cardiotoxicity: what\u2019s known and what\u2019s next","volume":"11","author":"Li","year":"2021","journal-title":"World J Psychiatry"},{"issue":"5","key":"10.1053\/j.ajkd.2026.07.006_bib54","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1161\/HYPERTENSIONAHA.122.20018","article-title":"Oral contraceptive pills and hypertension: a review of current evidence and recommendations","volume":"80","author":"Cameron","year":"2023","journal-title":"Hypertension"},{"issue":"10","key":"10.1053\/j.ajkd.2026.07.006_bib55","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.23.01157","article-title":"PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.ajkd.2026.07.006_bib56","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"2","key":"10.1053\/j.ajkd.2026.07.006_bib29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.115.06487","article-title":"Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the Chronic Renal Insufficiency Cohort Study","volume":"67","author":"Thomas","year":"2016","journal-title":"Hypertension"},{"issue":"6","key":"10.1053\/j.ajkd.2026.07.006_bib30","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/j.ajkd.2018.06.018","article-title":"Optimized reference intervals for plasma free metanephrines in patients with CKD","volume":"72","author":"Pamporaki","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2026.07.006_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/M20-4873","article-title":"Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: a retrospective cohort study","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1053\/j.ajkd.2026.07.006_bib33","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an Endocrine Society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1053\/j.ajkd.2026.07.006_bib34","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S2213-8587(25)00263-3","article-title":"Post-treatment renin status and cardiovascular, renal, and mortality outcomes in medically treated primary aldosteronism: a systematic review and meta-analysis","volume":"13","author":"Katsuragawa","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/jch.12914","article-title":"Effects of treating primary aldosteronism on renal function","volume":"19","author":"Kramers","year":"2017","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib36","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1161\/HYPERTENSIONAHA.119.13131","article-title":"Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function","volume":"74","author":"Kobayashi","year":"2019","journal-title":"Hypertension"},{"issue":"10","key":"10.1053\/j.ajkd.2026.07.006_bib37","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1161\/HYPERTENSIONAHA.123.21474","article-title":"Primary aldosteronism in chronic kidney disease: blood pressure control and kidney and cardiovascular outcomes after surgical versus medical management","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"issue":"25","key":"10.1053\/j.ajkd.2026.07.006_bib38","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1161\/CIRCULATIONAHA.112.091223","article-title":"The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients","volume":"125","author":"Olin","year":"2012","journal-title":"Circulation"},{"issue":"14","key":"10.1053\/j.ajkd.2026.07.006_bib39","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jacc.2016.01.058","article-title":"Smoking and adverse outcomes in fibromuscular dysplasia: U.S. registry report","volume":"67","author":"O\u2019Connor","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1053\/j.ajkd.2026.07.006_bib40","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1097\/HJH.0000000000000372","article-title":"Effects of continuous positive airway pressure on blood pressure in patients with resistant hypertension and obstructive sleep apnea: a meta-analysis","volume":"32","author":"Iftikhar","year":"2014","journal-title":"J Hypertens"},{"issue":"24","key":"10.1053\/j.ajkd.2026.07.006_bib41","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa1306187","article-title":"CPAP, weight loss, or both for obstructive sleep apnea","volume":"370","author":"Chirinos","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2026.07.006_bib42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5664\/jcsm.2420","article-title":"Effect of oral appliances on blood pressure in obstructive sleep apnea: a systematic review and meta-analysis","volume":"9","author":"Iftikhar","year":"2013","journal-title":"J Clin Sleep Med"},{"issue":"13","key":"10.1053\/j.ajkd.2026.07.006_bib43","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/jama.2023.17465","article-title":"Adherence to CPAP treatment and the risk of recurrent cardiovascular events: a meta-analysis","volume":"330","author":"Sanchez-de-la-Torre","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1053\/j.ajkd.2026.07.006_bib57","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","article-title":"Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials","volume":"42","author":"Neter","year":"2003","journal-title":"Hypertension"},{"issue":"5","key":"10.1053\/j.ajkd.2026.07.006_bib58","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/jch.14661","article-title":"Effect of weight loss on blood pressure changes in overweight patients: a systematic review and meta-analysis","volume":"25","author":"Yang","year":"2023","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"11","key":"10.1053\/j.ajkd.2026.07.006_bib59","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.jash.2018.09.007","article-title":"Effect of sleeve gastrectomy on hypertension","volume":"12","author":"Samson","year":"2018","journal-title":"J Am Soc Hypertens"},{"issue":"11","key":"10.1053\/j.ajkd.2026.07.006_bib60","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/CIRCULATIONAHA.117.032130","article-title":"Effects of bariatric surgery in obese patients with hypertension: the GATEWAY randomized trial (gastric bypass to treat obese patients with steady hypertension)","volume":"137","author":"Schiavon","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1053\/j.ajkd.2026.07.006_bib61","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s11605-008-0759-5","article-title":"Resolution of systemic hypertension after laparoscopic gastric bypass","volume":"13","author":"Hinojosa","year":"2009","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"10.1053\/j.ajkd.2026.07.006_bib62","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ajh\/hpaf205","article-title":"GLP-1 receptor agonists and blood pressure: a state-of-the-art review of mechanisms, evidence, and clinical implications","volume":"39","author":"Moiz","year":"2026","journal-title":"Am J Hypertens"},{"issue":"11","key":"10.1053\/j.ajkd.2026.07.006_bib63","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.3390\/jcm14113791","article-title":"Weight regain after liraglutide, semaglutide or tirzepatide interruption: a narrative review of randomized studies","volume":"14","author":"Quarenghi","year":"2025","journal-title":"J Clin Med"},{"issue":"3 suppl 1","key":"10.1053\/j.ajkd.2026.07.006_bib64","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2026.07.006_bib65","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ajcn\/nqac067","article-title":"Blood pressure interactions with the DASH dietary pattern, sodium, and potassium: the International Study of Macro-\/Micronutrients and Blood Pressure (INTERMAP)","volume":"116","author":"Chan","year":"2022","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib66","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/HYPERTENSIONAHA.118.12259","article-title":"Mediterranean-style diet improves systolic blood pressure and arterial stiffness in older adults","volume":"73","author":"Jennings","year":"2019","journal-title":"Hypertension"},{"issue":"11","key":"10.1053\/j.ajkd.2026.07.006_bib67","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1681\/ASN.0000000873","article-title":"ASN kidney health guidance on potassium and phosphorus food additives","volume":"36","author":"Biruete","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2026.07.006_bib68","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1080\/09637480701690519","article-title":"An investigation into the bioaccessibility of potassium in unprocessed fruits and vegetables","volume":"59","author":"Naismith","year":"2008","journal-title":"Int J Food Sci Nutr"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib69","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2215\/CJN.02430312","article-title":"A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate","volume":"8","author":"Goraya","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2026.07.006_bib70","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/s41591-023-02286-8","article-title":"Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial","volume":"29","author":"Yuan","year":"2023","journal-title":"Nat Med"},{"issue":"12","key":"10.1053\/j.ajkd.2026.07.006_bib71","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa2105675","article-title":"Effect of salt substitution on cardiovascular events and death","volume":"385","author":"Neal","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2026.07.006_bib72","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12916-026-04635-z","article-title":"Comparative effects of salt substitutes on blood pressure, cardiovascular events and mortality: a systematic review and network meta-analysis","volume":"24","author":"Lai","year":"2026","journal-title":"BMC Med"},{"issue":"6","key":"10.1053\/j.ajkd.2026.07.006_bib73","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.jrn.2017.10.005","article-title":"Diet quality of chronic kidney disease patients and the impact of nutritional counseling","volume":"28","author":"Fernandes","year":"2018","journal-title":"J Ren Nutr"},{"issue":"7","key":"10.1053\/j.ajkd.2026.07.006_bib74","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.tjnut.2024.05.008","article-title":"Fruit and vegetable intake patterns, kidney failure, and mortality in adults with and without chronic kidney disease in the United States","volume":"154","author":"Kranz","year":"2024","journal-title":"J Nutr"},{"issue":"4","key":"10.1053\/j.ajkd.2026.07.006_bib75","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1053\/j.jrn.2019.09.008","article-title":"Association between dietary patterns and kidney function in patients with chronic kidney disease: a cross-sectional analysis of the German Chronic Kidney Disease Study","volume":"30","author":"Heindel","year":"2020","journal-title":"J Ren Nutr"},{"key":"10.1053\/j.ajkd.2026.07.006_bib76","article-title":"Dietary Patterns and Risk of Type 2 Diabetes: A Systematic Review","author":"Talegawkar","year":"2024","journal-title":"USDA Nutrition Evidence Systematic Review"},{"issue":"1","key":"10.1053\/j.ajkd.2026.07.006_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.advnut.2023.09.011","article-title":"The role of diet in the prevention of hypertension and management of blood pressure: an umbrella review of meta-analyses of interventional and observational studies","volume":"15","author":"Aljuraiban","year":"2024","journal-title":"Adv Nutr"},{"issue":"536","key":"10.1053\/j.ajkd.2026.07.006_bib78","article-title":"Ultra-processed food consumption in youth and adults: United States, August 2021-August 2023","author":"Williams","year":"2025","journal-title":"NCHS Data Brief"},{"issue":"10","key":"10.1053\/j.ajkd.2026.07.006_bib79","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1038\/s41591-025-03910-5","article-title":"Ultra-processed diets promote excess calorie consumption","volume":"31","author":"Nestle","year":"2025","journal-title":"Nat Med"},{"key":"10.1053\/j.ajkd.2026.07.006_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2026.108097","article-title":"The addicted brain: how processed foods hijack reward pathways","volume":"224","author":"Hough","year":"2026","journal-title":"Pharmacol Res"},{"key":"10.1053\/j.ajkd.2026.07.006_bib81","series-title":"The Role of Nutrition in Maintaining Health in the Nation\u2019s Elderly: Evaluating Coverage of Nutrition Services for the Medicare Population","year":"2000"},{"issue":"10","key":"10.1053\/j.ajkd.2026.07.006_bib82","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jand.2018.05.023","article-title":"Medical nutrition therapy for patients with non-dialysis-dependent chronic kidney disease: barriers and solutions","volume":"118","author":"Kramer","year":"2018","journal-title":"J Acad Nutr Diet"},{"issue":"6","key":"10.1053\/j.ajkd.2026.07.006_bib83","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1053\/j.akdh.2023.12.001","article-title":"Medical nutrition therapy for chronic kidney disease: low access and utilization","volume":"30","author":"Lee","year":"2023","journal-title":"Adv Kidney Dis Health"},{"issue":"11","key":"10.1053\/j.ajkd.2026.07.006_bib86","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1681\/ASN.0000000512","article-title":"ASN kidney health guidance on the management of obesity in persons living with kidney diseases","volume":"35","author":"Ikizler","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2026.07.006_bib87","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/6666171","article-title":"Ketogenic diet: a review of composition diversity, mechanism of action and clinical application","volume":"2024","author":"Malinowska","year":"2024","journal-title":"J Nutr Metab"},{"issue":"13","key":"10.1053\/j.ajkd.2026.07.006_bib88","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"issue":"9731","key":"10.1053\/j.ajkd.2026.07.006_bib89","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"10.1053\/j.ajkd.2026.07.006_bib90","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"10.1053\/j.ajkd.2026.07.006_bib91","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"19","key":"10.1053\/j.ajkd.2026.07.006_bib92","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"issue":"10","key":"10.1053\/j.ajkd.2026.07.006_bib93","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study","volume":"123","author":"Peterson","year":"1995","journal-title":"Ann Intern Med"},{"issue":"9069","key":"10.1053\/j.ajkd.2026.07.006_bib94","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"9176","key":"10.1053\/j.ajkd.2026.07.006_bib95","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.ajkd.2026.07.006_bib96","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"issue":"23","key":"10.1053\/j.ajkd.2026.07.006_bib97","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib98","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1053\/j.ajkd.2009.09.014","article-title":"Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study","volume":"55","author":"Muntner","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"23","key":"10.1053\/j.ajkd.2026.07.006_bib99","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/2047487313510678","article-title":"The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial","volume":"21","author":"Heerspink","year":"2014","journal-title":"Eur J Prev Cardiol"},{"issue":"20","key":"10.1053\/j.ajkd.2026.07.006_bib101","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1053\/j.ajkd.2026.07.006_bib102","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2026.07.006_bib103","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41598-025-25632-x","article-title":"Hyperpolypharmacy in patients with chronic kidney disease and its impact on clinical outcomes","volume":"16","author":"Mouheb","year":"2026","journal-title":"Sci Rep"},{"issue":"27","key":"10.1053\/j.ajkd.2026.07.006_bib104","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib105","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.ajkd.2010.02.348","article-title":"Low medication adherence and hypertension control among adults with CKD: data from the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study","volume":"56","author":"Muntner","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2026.07.006_bib106","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000321688","article-title":"Adherence to antihypertensive agents and blood pressure control in chronic kidney disease","volume":"32","author":"Schmitt","year":"2010","journal-title":"Am J Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2026.07.006_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100912","article-title":"Antihypertensive treatment patterns in CKD stages 3 and 4: the CKD-REIN Cohort Study","volume":"6","author":"Costes-Albrespic","year":"2024","journal-title":"Kidney Med"},{"issue":"2","key":"10.1053\/j.ajkd.2026.07.006_bib108","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","article-title":"Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis","volume":"77","author":"Parati","year":"2021","journal-title":"Hypertension"},{"issue":"5","key":"10.1053\/j.ajkd.2026.07.006_bib109","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1161\/HYPERTENSIONAHA.122.20810","article-title":"Improved persistence to medication, decreased cardiovascular events and reduced all-cause mortality in hypertensive patients with use of single-pill combinations: results from the START-Study","volume":"80","author":"Schmieder","year":"2023","journal-title":"Hypertension"},{"issue":"6","key":"10.1053\/j.ajkd.2026.07.006_bib110","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJM199808063390607","article-title":"Diuretic therapy","volume":"339","author":"Brater","year":"1998","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2026.07.006_bib111","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib112","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000112270","article-title":"Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease","volume":"28","author":"Palmer","year":"2008","journal-title":"Am J Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2026.07.006_bib113","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/pharmaceutics12080713","article-title":"Prevalence of potential drug-drug interaction risk among chronic kidney disease patients in a Spanish hospital","volume":"12","author":"Santos-D\u00edaz","year":"2020","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1053\/j.ajkd.2026.07.006_bib114","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41371-020-0331-7","article-title":"Pharmacist\u2019s role in hypertension management: a review of key randomized controlled trials","volume":"34","author":"Wagner","year":"2020","journal-title":"J Hum Hypertens"},{"issue":"5","key":"10.1053\/j.ajkd.2026.07.006_bib115","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.amjhyper.2004.01.007","article-title":"A longitudinal analysis of antihypertensive drug interactions in a Medicaid population","volume":"17","author":"Carter","year":"2004","journal-title":"Am J Hypertens"},{"issue":"12","key":"10.1053\/j.ajkd.2026.07.006_bib116","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41371-025-01081-x","article-title":"A comprehensive global review on pharmacist-led strategies to support medication therapy in hypertensive patients","volume":"39","author":"Khan","year":"2025","journal-title":"J Hum Hypertens"},{"issue":"12","key":"10.1053\/j.ajkd.2026.07.006_bib117","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","article-title":"Intensive blood-pressure control in patients with type 2 diabetes","volume":"392","author":"Bi","year":"2025","journal-title":"N Engl J Med"},{"issue":"10449","key":"10.1053\/j.ajkd.2026.07.006_bib118","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","article-title":"Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial","volume":"404","author":"Liu","year":"2024","journal-title":"Lancet"},{"issue":"14","key":"10.1053\/j.ajkd.2026.07.006_bib119","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2026.07.006_bib120","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/jamainternmed.2020.5028","article-title":"Concordance between blood pressure in the systolic blood pressure intervention trial and in routine clinical practice","volume":"180","author":"Drawz","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1053\/j.ajkd.2026.07.006_bib121","doi-asserted-by":"crossref","DOI":"10.1111\/jch.70216","article-title":"Trends in hypertension prevalence and control in the United States over 25 years","volume":"28","author":"Saleh","year":"2026","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"10.1053\/j.ajkd.2026.07.006_bib122","article-title":"Blood pressure targets in adults with hypertension: a clinical practice guideline from the AAFP","volume":"106","author":"Coles","year":"2022","journal-title":"Am Fam Physician"},{"issue":"4","key":"10.1053\/j.ajkd.2026.07.006_bib123","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/HJH.0000000000004240","article-title":"Family medicine organizations: missing stakeholders in the 2025 ACC\/AHA hypertension guideline","volume":"44","author":"Le\u00f3n","year":"2026","journal-title":"J Hypertens"},{"issue":"1","key":"10.1053\/j.ajkd.2026.07.006_bib125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12882-022-03054-5","article-title":"Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia","volume":"24","author":"Kanda","year":"2023","journal-title":"BMC Nephrol"},{"issue":"11 suppl","key":"10.1053\/j.ajkd.2026.07.006_bib126","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"issue":"10","key":"10.1053\/j.ajkd.2026.07.006_bib127","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2337\/dc17-0885","article-title":"Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial","volume":"40","author":"Bress","year":"2017","journal-title":"Diabetes Care"},{"issue":"9982","key":"10.1053\/j.ajkd.2026.07.006_bib128","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"issue":"17","key":"10.1053\/j.ajkd.2026.07.006_bib129","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1053\/j.ajkd.2026.07.006_bib130","first-page":"2294","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"374","author":"Wright","year":"2016","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2026.07.006_bib131","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"4","key":"10.1053\/j.ajkd.2026.07.006_bib132","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1053\/j.ajkd.2026.07.006_bib133","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"19","key":"10.1053\/j.ajkd.2026.07.006_bib134","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/heartjnl-2024-324170","article-title":"Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial","volume":"110","author":"Krumholz","year":"2024","journal-title":"Heart"},{"issue":"5","key":"10.1053\/j.ajkd.2026.07.006_bib135","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1053\/j.ajkd.2026.07.006_bib136","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/dom.13978","article-title":"Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial","volume":"22","author":"Blonde","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"10.1053\/j.ajkd.2026.07.006_bib137","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.3390\/diagnostics14242829","article-title":"Gastrointestinal safety assessment of GLP-1 receptor agonists in the US: a real-world adverse events analysis from the FAERS Database","volume":"14","author":"Osei","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1053\/j.ajkd.2026.07.006_bib138","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12872-025-04640-9","article-title":"The role of bariatric surgery in hypertension control: a systematic review and meta-analysis with extended benefits on metabolic factors","volume":"25","author":"Dastjerdi","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"issue":"9","key":"10.1053\/j.ajkd.2026.07.006_bib139","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"10.1053\/j.ajkd.2026.07.006_bib140","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"issue":"12","key":"10.1053\/j.ajkd.2026.07.006_bib141","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2026.07.006_bib142","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib143","doi-asserted-by":"crossref","first-page":"172","DOI":"10.7326\/0003-4819-144-3-200602070-00005","article-title":"Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate","volume":"144","author":"Rahman","year":"2006","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1053\/j.ajkd.2026.07.006_bib144","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1681\/ASN.2018100971","article-title":"Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States","volume":"30","author":"Murphy","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2026.07.006_bib145","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1161\/HYP.0000000000000232","article-title":"Implementation strategies to improve blood pressure control in the United States: a scientific statement from the American Heart Association and American Medical Association","volume":"80","author":"Abdalla","year":"2023","journal-title":"Hypertension"},{"issue":"7","key":"10.1053\/j.ajkd.2026.07.006_bib146","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.004386","article-title":"Adapting and evaluating a health system intervention from Kaiser Permanente to improve hypertension management and control in a large network of safety-net clinics","volume":"11","author":"Fontil","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib147","first-page":"83","article-title":"A primer on quality assurance and performance improvement for interprofessional chronic kidney disease care: a path to Joint Commission certification","volume":"7","author":"Awdishu","year":"2019","journal-title":"Pharmacy (Basel)"},{"issue":"10285","key":"10.1053\/j.ajkd.2026.07.006_bib148","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.ajkd.2026.07.006_bib149","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ajog.2021.10.037","article-title":"Chronic kidney disease and adverse pregnancy outcomes: a systematic review and meta-analysis","volume":"226","author":"Al Khalaf","year":"2022","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2021.03.045","article-title":"Pregnancy outcomes in women with chronic kidney disease and chronic hypertension: a national cohort study","volume":"225","author":"Al Khalaf","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"19","key":"10.1053\/j.ajkd.2026.07.006_bib151","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2201295","article-title":"Treatment for mild chronic hypertension during pregnancy","volume":"386","author":"Tita","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.ajkd.2026.07.006_bib152","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1161\/HYPERTENSIONAHA.124.23411","article-title":"Predictive and diagnostic value of the angiogenic proteins in patients with chronic kidney disease","volume":"81","author":"Melamed","year":"2024","journal-title":"Hypertension"},{"issue":"5","key":"10.1053\/j.ajkd.2026.07.006_bib153","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.mayocp.2018.12.033","article-title":"Prevalence of apparent treatment-resistant hypertension in the United States according to the 2017 high blood pressure guideline","volume":"94","author":"Patel","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1053\/j.ajkd.2026.07.006_bib154","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.118.12191","article-title":"Prevalence of apparent treatment-resistant hypertension in the United States","volume":"73","author":"Carey","year":"2019","journal-title":"Hypertension"},{"issue":"8","key":"10.1053\/j.ajkd.2026.07.006_bib155","doi-asserted-by":"crossref","first-page":"810","DOI":"10.34067\/KID.0002072020","article-title":"Apparent treatment-resistant hypertension assessed by office and ambulatory blood pressure in chronic kidney disease\u2014a report from the Chronic Renal Insufficiency Cohort Study","volume":"1","author":"Thomas","year":"2020","journal-title":"Kidney360"},{"issue":"10008","key":"10.1053\/j.ajkd.2026.07.006_bib156","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.ajkd.2026.07.006_bib157","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1053\/j.ajkd.2026.07.006_bib158","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1053\/j.ajkd.2026.07.006_bib159","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41440-020-00570-5","article-title":"Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism","volume":"44","author":"Satoh","year":"2021","journal-title":"Hypertens Res"},{"issue":"9","key":"10.1053\/j.ajkd.2026.07.006_bib160","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/HYPERTENSIONAHA.124.22642","article-title":"Clinical management of primary aldosteronism: an update","volume":"81","author":"Rossi","year":"2024","journal-title":"Hypertension"},{"issue":"10367","key":"10.1053\/j.ajkd.2026.07.006_bib161","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.ajkd.2026.07.006_bib162","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.125.25563","article-title":"Aprocitentan in patients with chronic kidney disease and resistant hypertension","volume":"83","author":"Rossignol","year":"2026","journal-title":"Hypertension"},{"issue":"10234","key":"10.1053\/j.ajkd.2026.07.006_bib163","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial","volume":"395","author":"Bohm","year":"2020","journal-title":"Lancet"},{"issue":"10333","key":"10.1053\/j.ajkd.2026.07.006_bib164","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S0140-6736(22)00455-X","article-title":"Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial","volume":"399","author":"Mahfoud","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1053\/j.ajkd.2026.07.006_bib165","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/jamacardio.2022.3904","article-title":"Effects of renal denervation vs sham in resistant hypertension after medication escalation: prespecified analysis at 6 months of the RADIANCE-HTN TRIO randomized clinical trial","volume":"7","author":"Azizi","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1053\/j.ajkd.2026.07.006_bib166","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41440-022-01042-8","article-title":"Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial","volume":"46","author":"Kario","year":"2023","journal-title":"Hypertens Res"},{"issue":"8","key":"10.1053\/j.ajkd.2026.07.006_bib167","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.4244\/EIJ-D-22-00305","article-title":"Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial","volume":"18","author":"Rader","year":"2022","journal-title":"EuroIntervention"},{"issue":"12","key":"10.1053\/j.ajkd.2026.07.006_bib168","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1038\/s41440-024-01854-w","article-title":"36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO","volume":"47","author":"Bloch","year":"2024","journal-title":"Hypertens Res"},{"issue":"2","key":"10.1053\/j.ajkd.2026.07.006_bib169","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000004184","article-title":"Long-term effects of renal denervation on hypertension management: insights from an ESH Center of Excellence and a meta-analysis of current evidence","volume":"44","author":"Tsioufis","year":"2026","journal-title":"J Hypertens"},{"issue":"4","key":"10.1053\/j.ajkd.2026.07.006_bib170","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1053\/j.ajkd.2022.03.015","article-title":"Renal denervation: a review","volume":"80","author":"Rey-Garcia","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101606","article-title":"Long-term, patient-level analysis of radiofrequency renal denervation in the SYMPLICITY clinical trial program","volume":"4","author":"Mahfoud","year":"2025","journal-title":"JACC Adv"},{"issue":"12","key":"10.1053\/j.ajkd.2026.07.006_bib172","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/HYPERTENSIONAHA.125.25470","article-title":"Renal denervation in patients with moderate to severe chronic kidney disease","volume":"82","author":"Schlaich","year":"2025","journal-title":"Hypertension"},{"issue":"1","key":"10.1053\/j.ajkd.2026.07.006_bib173","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4244\/EIJ-D-19-00902","article-title":"Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation","volume":"16","author":"Townsend","year":"2020","journal-title":"EuroIntervention"},{"issue":"42","key":"10.1053\/j.ajkd.2026.07.006_bib174","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1093\/eurheartj\/ehz118","article-title":"Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry","volume":"40","author":"Mahfoud","year":"2019","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1053\/j.ajkd.2026.07.006_bib175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M20-4298","article-title":"Effects of intensive blood pressure treatment on orthostatic hypotension","volume":"174","author":"Juraschek","year":"2020","journal-title":"Ann Intern Med"},{"issue":"15","key":"10.1053\/j.ajkd.2026.07.006_bib176","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1001\/jama.2023.18497","article-title":"Orthostatic hypotension, hypertension treatment, and cardiovascular disease: an individual participant meta-analysis","volume":"330","author":"Juraschek","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1053\/j.ajkd.2026.07.006_bib177","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.xkme.2020.10.012","article-title":"Orthostatic hypertension and hypotension and outcomes in CKD: the CRIC (Chronic Renal Insufficiency Cohort) Study","volume":"3","author":"Rouabhi","year":"2021","journal-title":"Kidney Med"},{"issue":"3","key":"10.1053\/j.ajkd.2026.07.006_bib178","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/HYPERTENSIONAHA.119.14309","article-title":"Orthostatic hypotension, cardiovascular outcomes, and adverse events: results from SPRINT","volume":"75","author":"Juraschek","year":"2020","journal-title":"Hypertension"},{"issue":"2","key":"10.1053\/j.ajkd.2026.07.006_bib179","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jsxm.2019.11.256","article-title":"Effect of intensive vs standard blood pressure treatment upon erectile function in hypertensive men: findings from the Systolic Blood Pressure Intervention Trial","volume":"17","author":"Foy","year":"2020","journal-title":"J Sex Med"},{"issue":"13","key":"10.1053\/j.ajkd.2026.07.006_bib180","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/eurheartj\/ehad716","article-title":"Discontinuation vs. continuation of renin-angiotensin system inhibition before non-cardiac surgery: the SPACE trial","volume":"45","author":"Ackland","year":"2024","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1053\/j.ajkd.2026.07.006_bib181","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/M22-3157","article-title":"Hypotension-avoidance versus hypertension-avoidance strategies in noncardiac surgery: an international randomized controlled trial","volume":"176","author":"Marcucci","year":"2023","journal-title":"Ann Intern Med"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626010851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626010851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:07:53Z","timestamp":1792588073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626010851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":178,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0272638626010851"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.07.006","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KDOQI Commentary on the 2025 AHA\/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}